Ptiaglin – is highly selective dipeptidyl peptidase 4 (DPP-4) inhibitor for treatment of type 2 diabetes mellitus. By inhibiting DPP-4, sitagliptin increases the levels of two known incretin hormones GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). Incretin hormones are secreted in the intestinal tract for 24 fours, their levels increase in response to food ingestion. When blood glucose concentrations are normal or elevated, incretin hormones increase insulin synthesis and its secretion by pancreatic β-cells using cyclic adenosine monophosphate-associated signal intracellular mechanisms. In low blood glucose concentrations, the listed effects of incretins on insulin release and lowered glucagon secretion are not observed. GLP-1 and GIP have no effect on glucagon release in response to hypoglycemia.
Ptiaglin
Sitagliptin 25mg Tablets №28
Ptiaglin
Sitagliptin 50mg Tablets №28
Ptiaglin
Sitagliptin 100mg Tablets №28